Rallybio Corporation — Q1 2024 Form 10-Q Summary
Business context and reporting period
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases. The unaudited results cover the three months ended March 31, 2024. Lead programs are RLYB212, an anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia, and RLYB116, a C5 inhibitor for complement-mediated diseases. Neither program has received marketing approval, and the company has not generated product-sales revenue.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | No change disclosed |
| Research and development expense | $12.9 million | $11.2 million | +$1.7 million |
| General and administrative expense | $6.9 million | $7.2 million | -$0.3 million |
| Total operating expenses | $19.8 million | $18.4 million | +$1.4 million |
| Interest and other income, net | $1.4 million | $1.6 million | -$0.2 million |
| Loss on joint venture investment | $0.7 million | $0.6 million | +$0.1 million |
| Net loss | $19.0 million | $17.3 million | Loss increased $1.7 million |
| Net loss per share | $0.47 | $0.43 | Loss per share increased |
| Net cash used in operating activities | $15.5 million | $18.8 million | Use decreased $3.3 million |
The filing does not provide a meaningful gross margin or operating margin because Rallybio has no product revenue. Operating loss was $19.8 million. The company reported no debt or credit facility and no material financing commitments. Accrued expenses were $9.4 million at March 31, 2024, compared with $8.1 million at December 31, 2023.
At March 31, 2024, cash and cash equivalents were $19.3 million and marketable securities were $74.9 million, for total cash, cash equivalents and marketable securities of approximately $94.2 million. Total assets were $99.4 million, total liabilities were $10.2 million, and stockholders’ equity was $89.2 million. The company had an accumulated deficit of $254.3 million.
Material changes versus the prior comparable period
- Research and development expense increased 15%, primarily because of severance and other personnel costs associated with the workforce reduction; direct RLYB212 spending was broadly stable at $5.6 million.
- General and administrative expense declined modestly, as lower other administrative costs and insurance premiums offset severance-related costs.
- Operating cash use improved to $15.5 million from $18.8 million, partly due to working-capital changes and lower ongoing headcount.
- Cash and marketable securities declined from approximately $109.9 million at December 31, 2023 to $94.2 million at March 31, 2024.
- On February 6, 2024, Rallybio prioritized its portfolio around RLYB212 and eliminated approximately 45% of positions. It recorded approximately $3.3 million of restructuring charges, with substantially all payments expected by December 31, 2024.
- RLYB212 and RLYB116 program expenses were $5.6 million and $1.3 million, respectively, in Q1 2024. RLYB332 nonclinical studies were completed and additional data are expected in the second half of 2024.
Guidance, outlook, commentary, risks and unusual items
- Management plans to initiate a Phase 2 RLYB212 dose-confirmation trial in the second half of 2024 and expects the FNAIT natural history study to continue alongside the trial. Approximately 10,000 pregnant women had been screened as of May 1, 2024.
- Manufacturing-process enhancements for RLYB116 are expected to be completed in the second half of 2024.
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements into the middle of 2026, but states that substantial additional capital will be required to complete development and commercialization.
- On April 9, 2024, Rallybio entered a Johnson & Johnson collaboration related to FNAIT, receiving a $0.5 million upfront payment and becoming eligible for up to $3.7 million in additional payments subject to specified triggers.
- On April 10, 2024, Rallybio sold 3,636,363 shares to Johnson & Johnson Innovation–JJDC at $1.82 per share for approximately $6.6 million of gross proceeds. This post-quarter financing will dilute existing holders.
- Key risks include continued operating losses, dependence on additional financing, early-stage clinical and regulatory uncertainty, patient enrollment challenges for rare diseases, reliance on contract research and manufacturing organizations, potential companion-diagnostic requirements, competition, intellectual-property risks and possible safety issues.
- The company has no approved products, no product revenue, no committed external source of capital and no off-balance-sheet arrangements. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the RLYB212 Phase 2 trial begins on schedule in the second half of 2024 and whether regulators accept the proposed dose-confirmation and natural-history-study approach.
- Actual cash burn after the workforce reduction, restructuring payments and the April 2024 financing, and whether the projected funding runway to mid-2026 remains achievable.
- Terms, milestones and accounting treatment of the Johnson & Johnson collaboration and equity investment.
- RLYB116 manufacturing progress and any resulting decision to advance the program into further clinical testing.
- Clinical safety, efficacy, enrollment and regulatory developments for RLYB212 and RLYB116, including any companion-diagnostic requirements.
- Future equity issuance, including the $100 million at-the-market facility and approximately 3.3 million outstanding pre-funded warrants, which could increase dilution.